Treating necrotizing fasciitis with or without hyperbaric oxygen therapy

Zaheed Hassan, Robert F. Mullins, Bruce C. Friedman, Joseph R. Shaver, Claus Brandigi, Badrul Alam, Mohammad Mian

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

There is not enough clinical data to support the benefit of adjuvant HBO 2 therapy for necrotizing fasciitis (NF). We retrospectively reviewed our 67 NF cases to compare the outcomes of adjuvant HBO 2 therapy versus non-HBO 2 therapy. The overall outcome and morbidity criteria were compared between a group of 29 NF patients who received the adjuvant HBO 2 and a group of the remaining 38 NF patients treated by only surgery and other standards of care. This study did not find any difference between the groups in average length of hospital stay, and their mortality. However, six (25%) of the non-HBO 2 group patients required amputation of extremities compared to one of the HBO 2 group (Fisher exact p = 0.09). Although the benefit of adjuvant HBO 2 therapy remains controversial for NF, and the outcomes of this study are not statistically significant, there is a trend in clinical outcomes which shows that the therapy has the potential to reduce the number of amputation and salvage extremities. These findings necessitate multicenter, prospective, case control study to assess the possible benefit of adjuvant HBO 2 therapy for NF.

Original languageEnglish (US)
Pages (from-to)115-123
Number of pages9
JournalUndersea and Hyperbaric Medicine
Volume37
Issue number2
StatePublished - Mar 1 2010
Externally publishedYes

Fingerprint

Necrotizing Fasciitis
Hyperbaric Oxygenation
Amputation
Length of Stay
Therapeutics
Extremities
Standard of Care
Case-Control Studies
Outcome Assessment (Health Care)
Morbidity
Mortality

ASJC Scopus subject areas

  • Physiology (medical)
  • Pulmonary and Respiratory Medicine

Cite this

Hassan, Z., Mullins, R. F., Friedman, B. C., Shaver, J. R., Brandigi, C., Alam, B., & Mian, M. (2010). Treating necrotizing fasciitis with or without hyperbaric oxygen therapy. Undersea and Hyperbaric Medicine, 37(2), 115-123.

Treating necrotizing fasciitis with or without hyperbaric oxygen therapy. / Hassan, Zaheed; Mullins, Robert F.; Friedman, Bruce C.; Shaver, Joseph R.; Brandigi, Claus; Alam, Badrul; Mian, Mohammad.

In: Undersea and Hyperbaric Medicine, Vol. 37, No. 2, 01.03.2010, p. 115-123.

Research output: Contribution to journalArticle

Hassan, Z, Mullins, RF, Friedman, BC, Shaver, JR, Brandigi, C, Alam, B & Mian, M 2010, 'Treating necrotizing fasciitis with or without hyperbaric oxygen therapy', Undersea and Hyperbaric Medicine, vol. 37, no. 2, pp. 115-123.
Hassan Z, Mullins RF, Friedman BC, Shaver JR, Brandigi C, Alam B et al. Treating necrotizing fasciitis with or without hyperbaric oxygen therapy. Undersea and Hyperbaric Medicine. 2010 Mar 1;37(2):115-123.
Hassan, Zaheed ; Mullins, Robert F. ; Friedman, Bruce C. ; Shaver, Joseph R. ; Brandigi, Claus ; Alam, Badrul ; Mian, Mohammad. / Treating necrotizing fasciitis with or without hyperbaric oxygen therapy. In: Undersea and Hyperbaric Medicine. 2010 ; Vol. 37, No. 2. pp. 115-123.
@article{b1f0012b83104919876d2517005a4d8b,
title = "Treating necrotizing fasciitis with or without hyperbaric oxygen therapy",
abstract = "There is not enough clinical data to support the benefit of adjuvant HBO 2 therapy for necrotizing fasciitis (NF). We retrospectively reviewed our 67 NF cases to compare the outcomes of adjuvant HBO 2 therapy versus non-HBO 2 therapy. The overall outcome and morbidity criteria were compared between a group of 29 NF patients who received the adjuvant HBO 2 and a group of the remaining 38 NF patients treated by only surgery and other standards of care. This study did not find any difference between the groups in average length of hospital stay, and their mortality. However, six (25{\%}) of the non-HBO 2 group patients required amputation of extremities compared to one of the HBO 2 group (Fisher exact p = 0.09). Although the benefit of adjuvant HBO 2 therapy remains controversial for NF, and the outcomes of this study are not statistically significant, there is a trend in clinical outcomes which shows that the therapy has the potential to reduce the number of amputation and salvage extremities. These findings necessitate multicenter, prospective, case control study to assess the possible benefit of adjuvant HBO 2 therapy for NF.",
author = "Zaheed Hassan and Mullins, {Robert F.} and Friedman, {Bruce C.} and Shaver, {Joseph R.} and Claus Brandigi and Badrul Alam and Mohammad Mian",
year = "2010",
month = "3",
day = "1",
language = "English (US)",
volume = "37",
pages = "115--123",
journal = "Undersea and Hyperbaric Medicine",
issn = "1066-2936",
publisher = "Undersea and Hyperbaric Medical Society",
number = "2",

}

TY - JOUR

T1 - Treating necrotizing fasciitis with or without hyperbaric oxygen therapy

AU - Hassan, Zaheed

AU - Mullins, Robert F.

AU - Friedman, Bruce C.

AU - Shaver, Joseph R.

AU - Brandigi, Claus

AU - Alam, Badrul

AU - Mian, Mohammad

PY - 2010/3/1

Y1 - 2010/3/1

N2 - There is not enough clinical data to support the benefit of adjuvant HBO 2 therapy for necrotizing fasciitis (NF). We retrospectively reviewed our 67 NF cases to compare the outcomes of adjuvant HBO 2 therapy versus non-HBO 2 therapy. The overall outcome and morbidity criteria were compared between a group of 29 NF patients who received the adjuvant HBO 2 and a group of the remaining 38 NF patients treated by only surgery and other standards of care. This study did not find any difference between the groups in average length of hospital stay, and their mortality. However, six (25%) of the non-HBO 2 group patients required amputation of extremities compared to one of the HBO 2 group (Fisher exact p = 0.09). Although the benefit of adjuvant HBO 2 therapy remains controversial for NF, and the outcomes of this study are not statistically significant, there is a trend in clinical outcomes which shows that the therapy has the potential to reduce the number of amputation and salvage extremities. These findings necessitate multicenter, prospective, case control study to assess the possible benefit of adjuvant HBO 2 therapy for NF.

AB - There is not enough clinical data to support the benefit of adjuvant HBO 2 therapy for necrotizing fasciitis (NF). We retrospectively reviewed our 67 NF cases to compare the outcomes of adjuvant HBO 2 therapy versus non-HBO 2 therapy. The overall outcome and morbidity criteria were compared between a group of 29 NF patients who received the adjuvant HBO 2 and a group of the remaining 38 NF patients treated by only surgery and other standards of care. This study did not find any difference between the groups in average length of hospital stay, and their mortality. However, six (25%) of the non-HBO 2 group patients required amputation of extremities compared to one of the HBO 2 group (Fisher exact p = 0.09). Although the benefit of adjuvant HBO 2 therapy remains controversial for NF, and the outcomes of this study are not statistically significant, there is a trend in clinical outcomes which shows that the therapy has the potential to reduce the number of amputation and salvage extremities. These findings necessitate multicenter, prospective, case control study to assess the possible benefit of adjuvant HBO 2 therapy for NF.

UR - http://www.scopus.com/inward/record.url?scp=77953032498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953032498&partnerID=8YFLogxK

M3 - Article

VL - 37

SP - 115

EP - 123

JO - Undersea and Hyperbaric Medicine

JF - Undersea and Hyperbaric Medicine

SN - 1066-2936

IS - 2

ER -